{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:18:39Z","timestamp":1785449919093,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,25]]},"DOI":"10.7759\/cureus.72351","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T08:34:57Z","timestamp":1729845297000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Apixaban, Rivaroxaban, Dabigatran, and Vitamin K Antagonists in Patients With Atrial Fibrillation and Liver Disease: A Network Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Sanam","family":"Shaikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautham Varun","family":"Krishna Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bansari","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhuja","family":"Sompalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihtisham","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandipkumar S","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin R","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areeba","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the American Heart Association","volume":"139","author":"Benjamin EJ","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, et al.. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019, 139:e56-e528. 10.1161\/CIR.0000000000000659","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.816082","article-title":"Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study","volume":"119","author":"Go AS","year":"2009","unstructured":"Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer DE. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation. 2009, 119:1363-9. 10.1161\/CIRCULATIONAHA.108.816082","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10153212","article-title":"Anticoagulation in atrial fibrillation cardioversion: what is crucial to take into account","volume":"10","author":"Luc\u00e0 F","year":"2021","unstructured":"Luc\u00e0 F, Giubilato S, Di Fusco SA, et al.. Anticoagulation in atrial fibrillation cardioversion: what is crucial to take into account. J Clin Med. 2021, 10:3212. 10.3390\/jcm10153212","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezw313","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"50","author":"Kirchhof P","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al.. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016, 50:e1-e88. 10.1093\/ejcts\/ezw313","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2014.06.014","article-title":"Direct oral anticoagulants: new drugs and new concepts","volume":"7","author":"Levy JH","year":"2014","unstructured":"Levy JH, Spyropoulos AC, Samama CM, Douketis J. Direct oral anticoagulants: new drugs and new concepts. JACC Cardiovasc Interv. 2014, 7:1333-51. 10.1016\/j.jcin.2014.06.014","journal-title":"JACC Cardiovasc Interv"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2022.0745","article-title":"Anticoagulation in patients with atrial fibrillation and liver cirrhosis","volume":"35","author":"Karapedi E","year":"2022","unstructured":"Karapedi E, Papadopoulos N, Trifylli EM, Koustas E, Deutsch M, Aloizos G. Anticoagulation in patients with atrial fibrillation and liver cirrhosis. Ann Gastroenterol. 2022, 35:557-67. 10.20524\/aog.2022.0745","journal-title":"Ann Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1673658","article-title":"Coagulation pathways, hemostasis, and thrombosis in liver failure","volume":"39","author":"Intagliata NM","year":"2018","unstructured":"Intagliata NM, Davis JP, Caldwell SH. Coagulation pathways, hemostasis, and thrombosis in liver failure. Semin Respir Crit Care Med. 2018, 39:598-608. 10.1055\/s-0038-1673658","journal-title":"Semin Respir Crit Care Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59020346","article-title":"Oral anticoagulation in patients with chronic liver disease","volume":"59","author":"Costache RS","year":"2023","unstructured":"Costache RS, Dragomiric\u0103 AS, Gheorghe BE, Balaban VD, Stanciu SM, Jinga M, Costache DO. Oral anticoagulation in patients with chronic liver disease. Medicina (Kaunas). 2023, 59:346. 10.3390\/medicina59020346","journal-title":"Medicina (Kaunas)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.528754","article-title":"Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban","volume":"12","author":"Giorgi MA","year":"2011","unstructured":"Giorgi MA, Cohen Arazi H, Gonzalez CD, Di Girolamo G. Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban. Expert Opin Pharmacother. 2011, 12:567-77. 10.1517\/14656566.2011.528754","journal-title":"Expert Opin Pharmacother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13397","article-title":"Direct oral anticoagulants and advanced liver disease: a systematic review and meta-analysis","volume":"51","author":"Menichelli D","year":"2021","unstructured":"Menichelli D, Ronca V, Di Rocco A, Pignatelli P, Marco Podda G. Direct oral anticoagulants and advanced liver disease: a systematic review and meta-analysis. Eur J Clin Invest. 2021, 51:e13397. 10.1111\/eci.13397","journal-title":"Eur J Clin Invest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.62606","article-title":"Effectiveness of direct oral anticoagulants and vitamin K antagonists in preventing stroke in patients with atrial fibrillation and liver cirrhosis: a systematic review and meta-analysis","volume":"16","author":"Sinha T","year":"2024","unstructured":"Sinha T, Kaur M, Mayow AH, et al.. Effectiveness of direct oral anticoagulants and vitamin K antagonists in preventing stroke in patients with atrial fibrillation and liver cirrhosis: a systematic review and meta-analysis. Cureus. 2024, 16:e62606. 10.7759\/cureus.62606","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2023.130605","article-title":"Assessment of the efficiency and safety of anti-coagulation therapy in patients with liver cirrhosis and atrial fibrillation","volume":"9","author":"Baylo A","year":"2023","unstructured":"Baylo A, Cherniavskyi V, Reshotko D. Assessment of the efficiency and safety of anti-coagulation therapy in patients with liver cirrhosis and atrial fibrillation. Clin Exp Hepatol. 2023, 9:265-71. 10.5114\/ceh.2023.130605","journal-title":"Clin Exp Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2024.03.024","article-title":"Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: a multinational cohort study","volume":"237","author":"Douros A","year":"2024","unstructured":"Douros A, Cui Y, Platt RW, Filion KB, Sebastiani G, Renoux C. Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: a multinational cohort study. Thromb Res. 2024, 237:71-8. 10.1016\/j.thromres.2024.03.024","journal-title":"Thromb Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-024-03689-3","article-title":"Efficacy and safety of dabigatran and rivaroxaban in atrial fibrillation patients with impaired liver function: a multicenter retrospective cohort study","volume":"80","author":"Huang X","year":"2024","unstructured":"Huang X, Xu W, Wu G, et al.. Efficacy and safety of dabigatran and rivaroxaban in atrial fibrillation patients with impaired liver function: a multicenter retrospective cohort study. Eur J Clin Pharmacol. 2024, 80:1141-50. 10.1007\/s00228-024-03689-3","journal-title":"Eur J Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.060687","article-title":"Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study","volume":"147","author":"Lawal OD","year":"2023","unstructured":"Lawal OD, Aronow HD, Shobayo F, et al.. Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study. Circulation. 2023, 147:782-94. 10.1161\/CIRCULATIONAHA.122.060687","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011112","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulant and warfarin in cirrhotic patients with nonvalvular atrial fibrillation","volume":"8","author":"Lee HF","year":"2019","unstructured":"Lee HF, Chan YH, Chang SH, et al.. Effectiveness and safety of non-vitamin K antagonist oral anticoagulant and warfarin in cirrhotic patients with nonvalvular atrial fibrillation. J Am Heart Assoc. 2019, 8:e011112. 10.1161\/JAHA.118.011112","journal-title":"J Am Heart Assoc"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.04.052","article-title":"Direct oral anticoagulants in patients with atrial fibrillation and liver disease","volume":"73","author":"Lee SR","year":"2019","unstructured":"Lee SR, Lee HJ, Choi EK, et al.. Direct oral anticoagulants in patients with atrial fibrillation and liver disease. J Am Coll Cardiol. 2019, 73:3295-308. 10.1016\/j.jacc.2019.04.052","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7326\/M23-3067","article-title":"Comparative effectiveness and safety of apixaban, rivaroxaban, and warfarin in patients with cirrhosis and atrial fibrillation: a nationwide cohort study","volume":"177","author":"Simon TG","year":"2024","unstructured":"Simon TG, Singer DE, Zhang Y, Mastrorilli JM, Cervone A, DiCesare E, Lin KJ. Comparative effectiveness and safety of apixaban, rivaroxaban, and warfarin in patients with cirrhosis and atrial fibrillation: a nationwide cohort study. Ann Intern Med. 2024, 177:1028-38. 10.7326\/M23-3067","journal-title":"Ann Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.907197","article-title":"Effectiveness and safety of DOACs vs. warfarin in patients with atrial fibrillation and frailty: a systematic review and meta-analysis","volume":"9","author":"Zeng S","year":"2022","unstructured":"Zeng S, Zheng Y, Jiang J, Ma J, Zhu W, Cai X. Effectiveness and safety of DOACs vs. warfarin in patients with atrial fibrillation and frailty: a systematic review and meta-analysis. Front Cardiovasc Med. 2022, 9:907197. 10.3389\/fcvm.2022.907197","journal-title":"Front Cardiovasc Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-024-00608-5","article-title":"Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation combined with chronic kidney disease: a systematic review and meta-analysis","volume":"22","author":"Li Y","year":"2024","unstructured":"Li Y, Wu S, Zhou J, Zhang J. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation combined with chronic kidney disease: a systematic review and meta-analysis. Thromb J. 2024, 22:40. 10.1186\/s12959-024-00608-5","journal-title":"Thromb J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100222","article-title":"Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding","volume":"10","author":"Chang WH","year":"2021","unstructured":"Chang WH, Mueller SH, Tan YY, Lai AG. Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding. Lancet Reg Health Eur. 2021, 10:100222. 10.1016\/j.lanepe.2021.100222","journal-title":"Lancet Reg Health Eur"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.06.114","article-title":"A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: a comparison of efficacy and safety following treatment with direct oral anticoagulants","volume":"269","author":"Cohen AT","year":"2018","unstructured":"Cohen AT, Hill NR, Luo X, Masseria C, Abariga SA, Ashaye AO. A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: a comparison of efficacy and safety following treatment with direct oral anticoagulants. Int J Cardiol. 2018, 269:174-81. 10.1016\/j.ijcard.2018.06.114","journal-title":"Int J Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.016275","article-title":"Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis","volume":"48","author":"Bai Y","year":"2017","unstructured":"Bai Y, Deng H, Shantsila A, Lip GY. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis. Stroke. 2017, 48:970-6. 10.1161\/STROKEAHA.116.016275","journal-title":"Stroke"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1361405","article-title":"Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation","volume":"18","author":"Ageno W","year":"2017","unstructured":"Ageno W, Beyer-Westendorf J, Rubboli A. Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. Expert Opin Pharmacother. 2017, 18:1325-32. 10.1080\/14656566.2017.1361405","journal-title":"Expert Opin Pharmacother"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004925","article-title":"Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction","volume":"6","author":"Szummer K","year":"2017","unstructured":"Szummer K, Gasparini A, Eliasson S, et al.. Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. J Am Heart Assoc. 2017, 6:10.1161\/JAHA.116.004925","journal-title":"J Am Heart Assoc"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/joa3.13051","article-title":"Meta-analysis evaluating apixaban in patients with atrial fibrillation and end-stage renal disease requiring dialysis","volume":"40","author":"AlTurki A","year":"2024","unstructured":"AlTurki A, Marafi M, Dawas A, et al.. Meta-analysis evaluating apixaban in patients with atrial fibrillation and end-stage renal disease requiring dialysis. J Arrhythm. 2024, 40:440-7. 10.1002\/joa3.13051","journal-title":"J Arrhythm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/304416-comparison-of-apixaban-rivaroxaban-dabigatran-and-vitamin-k-antagonists-in-patients-with-atrial-fibrillation-and-liver-disease-a-network-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T08:35:01Z","timestamp":1729845301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/304416-comparison-of-apixaban-rivaroxaban-dabigatran-and-vitamin-k-antagonists-in-patients-with-atrial-fibrillation-and-liver-disease-a-network-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.72351","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}